Active tuberculosis: started on tuberculosis treatment · HIV‐positive and ‐negative adults and children
MVA85A showed no clear difference in active tuberculosis: started on tuberculosis treatment compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Cure or completion of treatment for active TB · Recipients of TB control services
The intervention showed no clear difference in cure or completion of treatment for active TB (low certainty).
1 finding from 1 review
Completion of treatment · people who are being treated for active VL
1 finding from 1 review
Intervention not reported
Treatment completion (at 6 months) · adults and children with active tuberculosis
1 finding from 1 review
Intervention not reported
Treatment completion · adults and children with active tuberculosis
It is very uncertain whether the intervention changes treatment completion (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus pyrazinamide leads to higher treatment‐limiting adverse events compared with isoniazid (high certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifapentine plus isoniazid weekly probably leads to higher treatment‐limiting adverse events compared with isoniazid daily (moderate certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
It is very uncertain whether rifampicin changes treatment‐limiting adverse events compared with isoniazid (very low certainty).
1 finding from 1 review
Treatment‐limiting adverse events · HIV‐negative people at risk of TB infection1
Rifampicin plus isoniazid showed no clear difference in treatment‐limiting adverse events compared with isoniazid (low certainty).
1 finding from 1 review
Intervention not reported
Incidence of active tuberculosis · People with latent tuberculosis
1 finding from 1 review